June 11, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
In patients with severe hypertriglyceridemia, olezarsen lowered triglycerides and reduced acute pancreatitis events compared with placebo, researchers reported at the European Atherosclerosis Society Congress. André Zimerman, MD, PhD, professor of cardiology and head of clinical trials at Hospital Moinhos de Vento, Moinhos de Vento Medical School, Porto Alegre, Rio Grande do Sul, Brazil,
Olezarsen (Ionis) riduce trigliceridi 65.5% e pancreatite acuta 85% (NNT=9) in ipertrigliceridemia severa vs placebo (455 pazienti, EAS 2026). L'approvazione FDA apre mercato lipid-lowering per Ionis nel trattamento della ipertrigliceridemia severa.
June 11, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease - AstraZeneca

Olezarsen indicated as an adjunct to diet

The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk…

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute…

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at…

OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS)…